Septerna, Inc. cash flow statement
In fiscal 2025, Septerna, Inc.'s operations generated $110m of cash; it spent $518,000 on capital projects, leaving free cash flow of $110m.
Cash flow statement
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −17 | −21 | −23 | −20 | 169 | −15 | −26 | −22 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 1 | 1 | 1 | 2 | 3 | 3 | 6 | 5 |
| Capital spending | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Free cash flow | −17 | −22 | −24 | −20 | 169 | −15 | −26 | −22 |
| Free cash flow after stock pay | −18 | −23 | −25 | −22 | 166 | −18 | −32 | −27 |
Compare with peers
- Agios Pharmaceuticals, Inc. cash flow
- Kymera Therapeutics, Inc. cash flow
- Xencor Inc cash flow
- 4d Molecular Therapeutics, Inc. cash flow
- Verastem, Inc. cash flow
Head to head: AGIO vs SEPNKYMR vs SEPNSEPN vs XNCRFDMT vs SEPN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies